Asia Pacific Infertility Drugs Market Size & Outlook
Asia Pacific infertility drugs market, 2018-2030 (US$M)
Related Markets
Asia Pacific infertility drugs market highlights
- The Asia Pacific infertility drugs market generated a revenue of USD 874.7 million in 2023.
- The market is expected to grow at a CAGR of 6.9% from 2024 to 2030.
- In terms of segment, gonadotrophins was the largest revenue generating drug class in 2023.
- Gonadotrophins is the most lucrative drug class segment registering the fastest growth during the forecast period.
- Country-wise, China is expected to register the highest CAGR from 2024 to 2030.
Asia Pacific data book summary
| Market revenue in 2023 | USD 874.7 million |
| Market revenue in 2030 | USD 1,399.9 million |
| Growth rate | 6.9% (CAGR from 2023 to 2030) |
| Largest segment | Gonadotrophins |
| Fastest growing segment | Gonadotrophins |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Gonadotrophins, Aromatase Inhibitors, Selective Estrogen Receptor Modulators (SERMs), Dopamine Agonists |
| Key market players worldwide | Merck & Co Inc, Organon & Co Ordinary Shares, Abbott Laboratories, Novartis AG ADR, Bayer AG, Pfizer Inc, Teva Pharmaceutical Industries Ltd ADR, Sanofi SA, Mankind Pharma, Ferring |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 23.8% of the global infertility drugs market in 2023.
- Globally, Europe is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 1,399.9 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Infertility Drugs Market Scope
Infertility Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Asia Pacific infertility drugs market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to infertility drugs market will help companies and investors design strategic landscapes.
Gonadotrophins was the largest segment with a revenue share of 53.45% in 2023. Horizon Databook has segmented the Asia Pacific infertility drugs market based on gonadotrophins, aromatase inhibitors, selective estrogen receptor modulators (serms), dopamine agonists covering the revenue growth of each sub-segment from 2018 to 2030.
- Asia Pacific Infertility Drugs Drug Class Outlook (Revenue, USD Million, 2018-2030)
- Gonadotrophins
- Aromatase Inhibitors
- Selective Estrogen Receptor Modulators (SERMs)
- Dopamine Agonists
- Others
- Asia Pacific Infertility Drugs End Use Outlook (Revenue, USD Million, 2018-2030)
- Women
- Men
- Asia Pacific Infertility Drugs Distribution Channel Outlook (Revenue, USD Million, 2018-2030)
- Hospital Pharmacy
- Specialty & Retail Pharmacy
- Others
Reasons to subscribe to Asia Pacific infertility drugs market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Asia Pacific infertility drugs market databook
-
Our clientele includes a mix of infertility drugs market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific infertility drugs market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific infertility drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Asia Pacific infertility drugs market size, by country, 2018-2030 (US$M)
Asia Pacific Infertility Drugs Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
